VJHemOnc is committed to improving our service to you

iwNHL 2019 | Update on selinexor for myeloma and large cell lymphomas

VJHemOnc is committed to improving our service to you

John Kuruvilla

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, Canada, speaking at the 17th International Workshop on Non-Hodgkin Lymphoma, Boston, MA, discusses updates from the trial of selinexor, a first-in-class oral selective inhibitor of nuclear export – the protein XPO1 – in the treatment of multiple myeloma and large cell lymphomas.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter